Klaviyo, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
KVYO$20.43-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Unaudited)
| As of, | ||
|---|---|---|
| September 30, 2025 | December 31, 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $980,267 | $881,473 |
| Restricted cash | — | 375 |
| Accounts receivable, net of allowance for doubtful accounts | 61,244 | 43,095 |
| Deferred contract acquisition costs, current | 27,004 | 20,544 |
| Prepaid expenses and other current assets | 41,494 | 34,262 |
| Total current assets | 1,110,009 | 979,749 |
| Property and equipment, net | 67,267 | 48,200 |
| Right-of-use assets, net | 94,909 | 42,917 |
| Deferred contract acquisition costs, non-current | 39,706 | 32,527 |
| Restricted cash, non-current | 738 | 739 |
| Prepaid marketing expense | 137,973 | 153,346 |
| Other non-current assets | 14,458 | 15,830 |
| Total assets | $1,465,060 | $1,273,308 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $20,515 | $14,579 |
| Accrued expenses | 94,546 | 99,828 |
| Lease liabilities, current | 24,510 | 20,989 |
| Deferred revenue | 87,926 | 64,497 |
| Total current liabilities | 227,497 | 199,893 |
| Lease liabilities, non-current | 88,895 | 32,449 |
| Other non-current liabilities | 6,594 | 6,979 |
| Total liabilities | 322,986 | 239,321 |
| Stockholders’ Equity | ||
| Preferred stock: $0.001 par value; 100,000,000 shares authorized; 0 and 0 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively. | — | — |
| Series A common stock: $0.001 par value; 3,000,000,000 shares authorized; 137,345,197 and 88,956,301 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively. | 137 | 89 |
| Series B common stock: $0.001 par value; 350,000,000 shares authorized; 164,564,196 and 183,801,332 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively. | 165 | 184 |
| Additional paid-in capital | 2,025,753 | 1,878,899 |
| Accumulated deficit | (883,981) | (845,185) |
| Total stockholders’ equity | 1,142,074 | 1,033,987 |
| Total liabilities and stockholders’ equity | $1,465,060 | $1,273,308 |
The accompanying notes are an integral part of these condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.